arg_1
stringlengths
4
5.08k
round_1
float64
2
8
ann_1
float64
1
2
arg_2
stringlengths
8
2.19k
round_2
float64
1
7
ann_2
float64
1
2
annotation_name
stringclasses
131 values
is_attacks
int64
0
1
I have raised the following concerns which is necessary to make this manuscript more scientifically interesting.
null
null
What are the p53 status and the apoptosis signaling pathway function in N1S1 cells?
null
null
cancers14122959_makarova
0
This is an interesting scientific study, as it concerns the issue of hepatocellular carcinoma, it also has a clinical aspect.
null
null
TTFields frequency scan in rat N1S1 HCC cells.
null
null
cancers14122959_makarova
0
The authors suggested that the therapeutic effects of the combination were apoptosis via autophagy.
null
null
Author Response Please see attachment Author Response File: Author Response.docx
null
null
cancers14122959_makarova
0
Response 7: We thank the reviewer for this question.
null
null
In the animal study we have now added IHC examination of beclin-1 and of GRP78, a marker for ER stress, as described in results sub-section 3.4.
null
null
cancers14122959_makarova
0
In addition to IHC, I suggest performing western blot using PARP antibody where the full length and cleaved bands are observed in the same blot.
null
null
Point 6: Any explanation for why not using cloroquine in vivo to integrate better the in vitro data.
null
null
cancers14122959_makarova
0
I read the manuscript with interest and commend the authors for the work done in the area of liver cancer treatment.
null
null
Overall, the authors believe that this research demonstrates potential for concomitant TTFields and sorafenib application in the treatment of HCC.
null
null
cancers14122959_makarova
0
GRP78 levels in the groups treated with TTFields or sorafenib alone remained unchanged from the control, but were elevated 2-fold in the TTFields plus sorafenib group (Figure 4f).
null
null
Point 7: Why there is no error bar in the control group of all bar graphs?
null
null
cancers14122959_makarova
0
In this manuscript, the authors, Davidi et al have investigated the effect of TTFields in HCC cells and an animal model, alone or in combination with sorafenib.
null
null
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 relative to time-respective control; two-way ANOVA.
null
null
cancers14122959_makarova
0
HepG2 cells were treated for 6, 24, or 48 hours with 150 kHz TTFields, 3 µM sorafenib, or the two treatments combined, followed by Western blot examination of the autophagy markers beclin-1 and LC3 (d), the ER stress marker GRP78 (e), and the apoptosis marker cleaved PARP (f).
null
null
This might be helpful and make the in vitro data more relevant with the data shown in vivo.
null
null
cancers14122959_makarova
0
Response 4: We thank the reviewer for this comment.
null
null
Response 7: We thank the reviewer for this question.
null
null
cancers14122959_makarova
0
Point 1: In vitro experiments sub-section in Methods sections lacks many experimental details (e.g., type of plate/flask, plating overnight or not before experiment, number of plated cells).
null
null
Concomitant TTFields with Sorafenib Enhances Treatment Efficacy in Vivo: “Tumor histology and immunostaining for beclin-1 and LC3, GRP78, and cleaved PARP were performed to examine autophagy, ER stress, and apoptosis levels, respectively.
null
null
cancers14122959_makarova
0
As shown in the Figure 4 C and D, TTFields were found less effective in terms of reducing the tumors volume and weight when compared with sorafenib.
null
null
Were these western blots (Figure 3D-F) repeated 3 times as the material and method mentions?
null
null
cancers14122959_perova
0
Point 7: Why there is no error bar in the control group of all bar graphs?
null
null
Point 4: Since Annexin V/7-ADD data was not convincing and the authors observed the minor increase of apoptotic cells after HCC cells were treated with combination of TTFields and sorafenib (when compared to the cells treated with TTFields and sorafenib alone), I suggest to run the WBs to examine the expression of the cleaved forms of PARP and caspase-3 (for both HCC cell lines).
null
null
cancers14122959_perova
0
While I do not know if the authors have the technology to perform TTFields in mice, where for sure they should have done xenograft models with the two human cell lines, why the rat cell line was not studied in vitro using the same experimental strategies as for human cells.
null
null
However, I feel that the experiments around this concept were not designed well enough to support their new findings.
null
null
cancers14122959_perova
0
We thank the reviewer for this comment, as these additions add much clarity to the mechanism of action of TTFields in combination with sorafenib and provide a more coherent explanation for the in vivo results.
null
null
Point 9: Was Mycoplasma testing done routinely?
null
null
cancers14122959_perova
0
Similarly, low evidence of apoptosis (expression of cleaved PARP) was found in these groups, as shown in Figure 4F.
null
null
Overall, the authors believe that this research demonstrates potential for concomitant TTFields and sorafenib application in the treatment of HCC.
null
null
cancers14122959_perova
0
The materials and methods section are elaborated in the details.
null
null
However, the exact mechanism of the combination therapy induced cell death is not yet known as the activation of autophagy in the combination therapy was not increased.
null
null
cancers14122959_perova
0
These additions may be seen in Figure 3 and are described in results sub-section 3.4, Autophagy-apoptosis Interplay For Treatment with Concomitant TTFields and Sorafenib: “In order to investigate the mechanism of action of TTFields-sorafenib co-application, HepG2 and Huh-7D12 cells were treated for 6, 24, or 48 hours with TTFields, sorafenib (3µM), or the two modalities together, and then examined for expression levels of various proteins.
null
null
As a rule of thumb, when a housekeeping protein gives problems in immunoblotting, there are many other classic protein to switch the investigation (b-actin, vinculin, Ku, etc.).
null
null
cancers14122959_perova
0
However, the limited experimental design and paucity of strong data ask for more experiments to proof the feasibility of this combination for treating HCC.
null
null
Is this indeed an anti-tumor effect or a very toxic effect to the liver (including tumor).
null
null
cancers14122959_perova
0
While I do not know if the authors have the technology to perform TTFields in mice, where for sure they should have done xenograft models with the two human cell lines, why the rat cell line was not studied in vitro using the same experimental strategies as for human cells.
null
null
Also mention the ‘n’ number in all the experiments involved for invitro and invivo.
null
null
cancers14122959_perova
0
Majority of rodent study in cancer research lose the control group early but the treated groups are followed up for much longer to delineate indeed the efficacy vs. toxicity.
null
null
The authors suggested that the therapeutic effects of the combination were apoptosis via autophagy.
null
null
cancers14122959_perova
0
However, I feel that the experiments around this concept were not designed well enough to support their new findings.
null
null
The higher changes in expression levels and faster kinetics when TTFields and sorafenib were applied together rather than alone indicate higher stress levels imposed on the cells in the former case.” Figure 3.
null
null
cancers14122959_perova
0
Similar, the graphs illustrating the LC3 expression are not in a proper fit with the images shown in Figure 4D.
null
null
Point 9: Was Mycoplasma testing done routinely?
null
null
cancers14122959_perova
0
The in vivo model appears to be performed only time which question the validity of data.
null
null
Author Response Please see attachment Author Response File: Author Response.docx
null
null
cancers14122959_perova
0
The apoptosis marker cleaved PARP displayed increased expression in the combined group already after 24 hours, elevating even further after 48 hours of treatment.
null
null
Point 3: It will be much better to provide the data to explain the mechanisms illustrating why the monotherapy of TTFields or sorafenib induced autophagy, whereas the tumors treated with combination developed the substantial apoptotic death of tumor cells.
null
null
cancers14122959_perova
0
The rigor science recommends at least 2 independent experiments with at least 7 animals randomized per group.
null
null
At least one different dose should have been studied for comparison since this is a completely different tumor environment than the in vitro one.
null
null
cancers14122959_perova
0
We thank the reviewer for this comment, as these additions add much clarity to the mechanism of action of TTFields in combination with sorafenib and provide a more coherent explanation for the in vivo results.
null
null
Can this dose observed in vitro on only tumor cells be translated to in vivo work where the tumor microenvironment is totally different?
null
null
cancers14122959_perova
0
The authors indicated that TTField had potential to be a new treatment option of hepatocellular carcinoma.
null
null
I have raised the following concerns which is necessary to make this manuscript more scientifically interesting.
null
null
cancers14122959_perova
0
For the monotherapies, cleaved PARP increase was only evident at 48 hours of treatment, and to a lower extent than that in the co-treatment group (Figure 3f).
null
null
Response: We thank the reviewer for the positive review.
null
null
cancers14122959_perova
0
Were these western blots (Figure 3D-F) repeated 3 times as the material and method mentions?
null
null
Can this dose observed in vitro on only tumor cells be translated to in vivo work where the tumor microenvironment is totally different?
null
null
cancers14122959_perova
0
Were the mice perfused before collecting the tumors?
null
null
Point 8: Since sorafenib acts also on angiogenesis, did the authors investigate if TTFields may interfere with anti-angiogenic effect sorafenib-mediated?
null
null
cancers14122959_perova
0
Overall, the authors believe that this research demonstrates potential for concomitant TTFields and sorafenib application in the treatment of HCC.
null
null
Point 6: Any explanation for why not using cloroquine in vivo to integrate better the in vitro data.
null
null
cancers14122959_perova
0
The reference protein should have the same intensity since this is the control for equal protein loading.
null
null
The rigor science recommends at least 2 independent experiments with at least 7 animals randomized per group.
null
null
cancers14122959_perova
0
This might be achieved by using the combination of so-called Tumor Treating fields (TTFields) with targeted drug, I have the following suggestions about this manuscript: Point 1: The authors demonstrate the efficacy of TTFields in vivo even when used as monotherapy.
null
null
Point 1: In vitro experiments sub-section in Methods sections lacks many experimental details (e.g., type of plate/flask, plating overnight or not before experiment, number of plated cells).
null
null
cancers14122959_perova
0
Were the cells from supernatant counted (where are probably the majority of dead cells)?
null
null
Response 6: We thank the reviewer for this comment.
null
null
cancers14122959_perova
0
Moreover, there is a discrepancy between the fold changes in tumor weight vs. volume in the combination group vs. untreated group.
null
null
I read the manuscript with interest and commend the authors for the work done in the area of liver cancer treatment.
null
null
cancers14122959_perova
0
Point 1: In vitro experiments sub-section in Methods sections lacks many experimental details (e.g., type of plate/flask, plating overnight or not before experiment, number of plated cells).
null
null
Other important autophagy and degradation markers like Beclin1 and P62 need to be shown to reflect the regulatory mechanism of TTFields, as well as for the combined treatment with Sorafenib.
null
null
cancers14122959_perova
0
Point 1: In vitro experiments sub-section in Methods sections lacks many experimental details (e.g., type of plate/flask, plating overnight or not before experiment, number of plated cells).
null
null
Concomitant TTFields with Sorafenib Enhances Treatment Efficacy in Vivo: “Tumor histology and immunostaining for beclin-1 and LC3, GRP78, and cleaved PARP were performed to examine autophagy, ER stress, and apoptosis levels, respectively.
null
null
cancers14122959_perova
0
Author Response Please see attachment Author Response File: Author Response.docx
null
null
Is that timing enough to get protein expression?
null
null
cancers14122959_perova
0
Moreover, many bands belonging to all investigated proteins are truncated, fractured and I identified a lot of troubleshooting in bands due the presence of bubbling when running the blots.
null
null
The autophagy marker LC3 also displayed such bi-phasic characteristics, but with a somewhat slower kinetics, showing some elevation at 6 hours of treatment, but higher elevation at the 24 hours time point (Figure 3d).
null
null
cancers14122959_perova
0
The assay results enabled direct measurement of the percentage of the isoforms generated thus facilitating a better understanding of the dominant isoform generated by each variant and their effect on protein coding.
null
null
As such, in order to correlate the discussion in this paragraph with the information in table 2, the reader also needs to cross reference Table 1 or 3.
null
null
cancers14122960_makarova
0
I would also stress a little more that FL is almost undetectable.
null
null
Lines 342-359 – This paragraph discusses two RAD51C variants, c.404+3A>G and c.705+3A>G, for which mg-FL transcripts were detected in 26.3% and 21.3% or transcripts, respectively.
null
null
cancers14122960_makarova
0
The authors further used the minigene splicing assay results, and understanding of RAD51C protein biology, to evaluate each variant using the most current ACMG-AMP frameworks for variant classification.
null
null
Author Response Thank you very much for the positive comments 1-
null
null
cancers14122960_makarova
0
Is it known whether there is a threshold of RAD51C deficiency that is tolerated before associated cancer risks become increased?
null
null
The manuscript entitled "Minigene splicing assays identify 20 spliceogenic variants of the breast/ovarian cancer susceptibility gene RAD51C authored by Sanoguera-Miralles et al., is a very interesting study.
null
null
cancers14122960_makarova
0
However, the corresponding tables that summarizes variant classification according to the ACMG/AMP-based criteria (Table 2), does not include these transcript isoform names.
null
null
Although a reference is provided so that the reader can look up what these ad-hoc rules are, it would also be helpful to briefly describe these in the current manuscript.
null
null
cancers14122960_makarova
0
Leaking splicing was also noted in two instances resulting in detection of the canonical transcript in 26.3% and 21.3% of transcripts, respectively.
null
null
Although a reference is provided so that the reader can look up what these ad-hoc rules are, it would also be helpful to briefly describe these in the current manuscript.
null
null
cancers14122960_makarova
0
Is there evidence from another source that these beta strands are critical to protein function and that their loss is deleterious (rather than resulting in normal or slightly reduced protein activity)?
null
null
The transcript analysis results demonstrated splice complexity with several variants resulting in two or more transcript isoforms.
null
null
cancers14122960_makarova
0
While in silico prediction tools can provide insights to possible impacts of nucleotide variants on splicing, these prediction tools do not replace the empirical evidence that the minigene assay can provide.
null
null
These variant interpretations were generally evidence based and well thought out.
null
null
cancers14122960_makarova
0
Overall manuscript is well written, very relevant for variant analysis and is suitable for publication if they address the following concerns: 1)
null
null
The transcript analysis results demonstrated splice complexity with several variants resulting in two or more transcript isoforms.
null
null
cancers14122960_makarova
0
present an interesting manuscript that utilizes a minigene splicing assay to examine twenty RAD51C variants catalogued through ClinVar.
null
null
The manuscript is very well written, clear and well discussed; I have just few comments: in the Introduction in the sentence 61-69 the authors do not mention anything about BRCA1 (they mention MLH1 though); I would expect that as BRCA1 splice variants are deeply studied.
null
null
cancers14122960_makarova
0
The manuscript is very well written, clear and well discussed; I have just few comments: in the Introduction in the sentence 61-69 the authors do not mention anything about BRCA1 (they mention MLH1 though); I would expect that as BRCA1 splice variants are deeply studied.
null
null
Lines 342-359 – This paragraph discusses two RAD51C variants, c.404+3A>G and c.705+3A>G, for which mg-FL transcripts were detected in 26.3% and 21.3% or transcripts, respectively.
null
null
cancers14122960_makarova
0
Results section (Page 6, line 221): We investigated the association of NR2F1 expression with metastasis.
null
null
Cell proliferation-related gene sets were suppressed and MKi67 expression was lower in high NR2F1 BC.
null
null
cancers14122962_makarova
0
Discussion section (Page 13, line 427): The current study demonstrated that NR2F1 expression in the bulk tumor of primary breast cancer is associated with decreased cell proliferation and cancer stem cell-like characteristics.
null
null
In addition, it shows that NR2F1 is primarily expressed in CAFs, particularly in inflammatory CAFs.
null
null
cancers14122962_makarova
0
Conclusions: NR2F1 expression in breast cancer is associated with tumor dormancy traits and it is predominantly ex-pressed in CAFs in the tumor microenvironment.
null
null
Nat Cell Biol 2017), it is puzzling how NR2F1 in CAFs of the primary tumor would contribute to dormancy of DTCs.
null
null
cancers14122962_makarova
0
Can the authors do some analyses using data generated from both primary and metastatic tumors to check if there is any difference of NR2F1 expression, and how NR2F1 expression is correlated with metastasis?
null
null
Expression of NR2F1 between endocrine therapy responder and non-responder in hormone-positive primary breast cancer.
null
null
cancers14122962_makarova
0
Kaplan-Meier curves of overall survival (OS), disease- specific survival (DSS), and disease-free survival (DFS) based on the high and low NR2F1 expression in triple-negative breast cancer of three large cohorts.
null
null
(A) Boxplots showing various scores based on high and low NR2F1 expression in triple-negative breast cancer of TCGA; Intratumoral heterogeneity, homologous recombination deficiency (HRD), silent/non- silent mutation rate, SNV/Indel neoantigen, Interferon gamma response, fraction altered, tumor-infiltrating lymphocytes (TIL) fraction, and stromal fraction.
null
null
cancers14122962_makarova
0
Kaplan-Meier curves of overall survival (OS), disease- specific survival (DSS), and disease-free survival (DFS) based on the high and low NR2F1 expression in triple-negative breast cancer of three large cohorts.
null
null
Comment 2: The authors choose chemotherapy as a treatment option to compare it with NR2F1 levels.
null
null
cancers14122962_makarova
0
Previous studies mentioned that NR2F1 was highly expressed in DTCs [67].
null
null
Comment 3: Line 170, “Figure 1E” should be “Figure 1D”.
null
null
cancers14122962_makarova
0
In order to prove that CAF-expressed NR2F1 regulates breast tumor dormancy, one needs to analyze the single-cell sequencing data and show whether the late recurrence in other organs, such as lungs, bones, and brain, other than lymph nodes, is correlated with NR2F1 expression in the CAFs.
null
null
We found that NR2F1 is most predominantly expressed in CAFs in the TME of primary breast cancer.
null
null
cancers14122962_makarova
0
Comment 2: The authors choose chemotherapy as a treatment option to compare it with NR2F1 levels.
null
null
Methods: A total of 6758 transcriptomes of bulk tumors from multiple breast cancer patient cohorts and two single-cell sequence cohorts were analyzed.
null
null
cancers14122962_makarova
0
Results section (Page 11, line 346): There was no difference in NR2F1 expression between responder and non-responder to neoadjuvant endocrine therapy (Supplementary Fig. 9).
null
null
Thus, we investigated the clinical relevance of the expression of NR2F1, a known dormancy biomarker.
null
null
cancers14122962_perova
0
However, the findings from our study are not ample to substantiate that CAF-expressed NR2F1 regulates breast tumor dormancy.
null
null
Please find our point-by-point responses below.
null
null
cancers14122962_perova
0
Association of NR2F1 with immunity within the tumor microenvironment of HER2 positive breast cancer.
null
null
We found that NR2F1 is most predominantly expressed in CAFs in the TME of primary breast cancer.
null
null
cancers14122962_perova
0
Discussion section (Page 13, line 427): The current study demonstrated that NR2F1 expression in the bulk tumor of primary breast cancer is associated with decreased cell proliferation and cancer stem cell-like characteristics.
null
null
Man-Whitney U test was used to compare the two groups and p-values are shown in bold for significant results (p < 0.05).
null
null
cancers14122962_perova
0
Also, dot plots show the expression of NR2F1, TGFB1, SOX9, and RARB by cell type in each immunohistological subtype in single-cell Cohort 2.
null
null
To this end, we believe that NR2F1 expression in the bulk tumor does not reflect the expression in the cancer cells, thus its value as a biomarker is in doubt.
null
null
cancers14122962_perova
0
Results section (Page 11, line 346): There was no difference in NR2F1 expression between responder and non-responder to neoadjuvant endocrine therapy (Supplementary Fig. 9).
null
null
Kaplan-Meier curves of overall survival (OS), disease- specific survival (DSS), and disease-free survival (DFS) based on the high and low NR2F1 expression in triple-negative breast cancer of three large cohorts.
null
null
cancers14122962_perova
0
Log-rank test was used for the analysis, and significant p values are shown in bold.
null
null
Nat Cell Biol 2017), it is puzzling how NR2F1 in CAFs of the primary tumor would contribute to dormancy of DTCs.
null
null
cancers14122962_perova
0
Comment 2: The authors should clearly explain the innovation and importance of their work on the introduction of the manuscript.
null
null
They should justify the value of the work and compare their work with previously similar published papers.
null
null
catal12030290_makarova
0
According to the reviewer suggestion, the SEM images with same scale are provided in the revised manuscript.
null
null
Response: We acknowledge the reviewer’s opinion.
null
null
catal12030290_makarova
0
Comment 5: Why authors did not use XRD technique for sample characterization?
null
null
A point-by-point response to the reviewer-2 comments is appended below for your convenience.
null
null
catal12030290_makarova
0
Synthesis of bioadsorbent and evaluation of its structure using SEM and FT-IR spectroscopy.
null
null
Comment 2: The authors should clearly explain the innovation and importance of their work on the introduction of the manuscript.
null
null
catal12030290_makarova
0
: catalysts-1584262 Title: Bio-stimulated adsorption of Cr(VI) from aqueous solution by Groundnut Shell Activated Carbon@Al embedded material Response to Reviewer-2 Comments We appreciate the efforts of the reviewers for their detailed and insightful comments, which have helped us to improve the quality of our manuscript.
null
null
All the modifications are shown in yellow color in the revised manuscript.
null
null
catal12030290_makarova
0
We hope the reviewer understand the experimental deficiencies at the stage of the present experiments.
null
null
There are some points which must be edited or clarified by providing additional information or comments:
null
null
catal12030290_makarova
0
Comments to the Author Manuscript Catalysts-1584262 The manuscript entitled ‘Bio-stimulated adsorption of Cr(VI) from aqueous solution by Groundnut Shell Activated [email protected] embedded material’ by Rao et al focuses on the synthesis of bioadsorbent aluminum metal blended with groundnut shell activated carbon material (Al-GNSC) and it practical application for Cr(VI) adsorption from waste aqueous solutions.
null
null
Response: We acknowledge the reviewer’s opinion.
null
null
catal12030290_makarova
0
(ppm) pH Contact Time (min) Adsorbent dosage (g l-1) Maximum adsorption capability (mg g-1) References Activated carbon (AC) prepared from coconut tree sawdust 10 3.0 180 0.2 3.46 [29] Raw coconut fiber 250 1.0 270 10 18.60 [30] Sugarcane bagasse 100 2.0 90 10 1.76 [31] Canadian peat Coconut fiber 50 2.0 4320 25 4.61 4.71 [32] peanut shell (P. Shell), sawdust (S. Dust) and Cassia fistula leaves (C.F.
null
null
Comment 2: The porosity of the sample should be measured.
null
null
catal12030290_makarova
0
There are some points which must be edited or clarified by providing additional information or comments:
null
null
After making all required minor changes in article it could be recommended for publication.
null
null
catal12030290_makarova
0
Please add the discussion which peak shift is related to Cr, the authors can combine these with the discussion of the mechanism.
null
null
The authors are very thankful to the Reviewer for their valuable suggestions for the improvement of the manuscript.
null
null
catal12030290_makarova
0
Response: We acknowledge the reviewer’s opinion.
null
null
First of all, authors have to attach a EDX mapping images before/after sorption of chromium ions.
null
null
catal12030290_makarova
0
Response: We acknowledge the reviewer’s opinion.
null
null
The authors are very thankful to the Reviewer for their valuable suggestions for the improvement of the manuscript.
null
null
catal12030290_makarova
0
We hope the reviewer understand the experimental deficiencies at the stage of the present experiments.
null
null
Page 2 of 2 Comment 5: In the experiment, H2SO4 is added in the first step, what is the purpose?
null
null
catal12030290_makarova
0
Comment 9: The conclusion section should be elaborated and improved.
null
null
Response: We acknowledge the reviewer’s opinion.
null
null
catal12030290_makarova
0
Comment 8: In order to confirm proposed mechanism of Cr(VI) adsorption (illustrated on the fig 6) Authors should provide data on adsorption capacity of pristine groundnut shell activated carbon (not modified with Al).
null
null
Response: We acknowledge the reviewer’s opinion.
null
null
catal12030290_makarova
0
Examination of prepared adsorbents for Cr(VI) ions removal.
null
null
However, we regret that we were not able to investigate the BET analysis due to pandemic situation, which could definitely give us additional information.
null
null
catal12030290_makarova
0
The authors are very thankful to the Reviewer for their valuable suggestions for the improvement of the manuscript.
null
null
Is the products suitable for this real condition?
null
null
catal12030290_makarova
0
In such form is rather difficult to make adequate comparison.
null
null
Please add the discussion which peak shift is related to Cr, the authors can combine these with the discussion of the mechanism.
null
null
catal12030290_makarova
0
Furthermore, it should be justified why this difference does not influence the comparison of the results with the different cell lines (THP1, Jurkat, Raji).
null
null
– the activity of PLY/SLO was prevalent at the initial times of incubation and at relatively high amounts (volume) of supernatants, whereas SLS activity fully developed only after initial lag period but was prevalent when relatively low amounts of supernatants were used in the assays.
null
null
cells11010166_perova
0
Point-by-point response to reviewers: Reviewer 1 comments 1.
null
null
Its exact mode-of-action is still not yet fully clarified.
null
null
cells11010166_perova
0
However, given the poor characterization of SLS, its unavailability from commercial providers and its extremely tedious purification, the mechanistic details of the SLS neutralization will require an extensive a project of its own and are beyond the scope of the current study.
null
null
This control represents 100% survival and allows us to normalize our survival data.
null
null
cells11010166_perova
0
In one control we challenged the cells with bacterial supernatant without adding liposomes, to determine that the baseline cytotoxicity is in line with the results displayed in the Figure 1.
null
null
Figure 2 (for referee inspection only) demonstrates that Alamar blue cell viability assay and Trypan blue live/dead quantification provide results that are identical to those obtained in the cell proliferation protocol used in our study.
null
null
cells11010166_perova
0
The following text was added to the material and method section: The data were normalized to a control incubated with PBS instead of bacterial supernatant (considered as 0% cell death).
null
null
We hope that with these changes our manuscript will be considered for publication and we are looking forward to hearing from you.
null
null
cells11010166_perova
0
However, as the immune cell lines have different sensitivities depending on the toxin profile of the tested strain, a similar lethal dose corresponds to different supernatant volumes.
null
null
However, authors did not make any attempt to explore this aspect in mechanistic detail.
null
null
cells11010166_perova
0
Figure 2 (for referee inspection only) demonstrates that Alamar blue cell viability assay and Trypan blue live/dead quantification provide results that are identical to those obtained in the cell proliferation protocol used in our study.
null
null
It is not clear why they are calling the preparations as the nanotraps.
null
null
cells11010166_perova
0
However, I think that the article can be substantially improved if the following points are addressed: (1)
null
null
However, I think that the article can be substantially improved if the following points are addressed: (1)
null
null
cosmetics2030248_makarova
0
All the experiments shown are necessary and sufficient to support the conclusions.
null
null
Round 1: and Author Response The article titled “Thermal behavior and free-radical-scavenging activity of phytic acid alone and incorporated in galenic emulsions” is focused on the characterization of phytic acid stability and use in cosmetic formulas.
null
null
cosmetics2030248_makarova
0
The article is well written, and the overall study was well planned and professionally conducted.
null
null
Round 1: and Author Response The article titled “Thermal behavior and free-radical-scavenging activity of phytic acid alone and incorporated in galenic emulsions” is focused on the characterization of phytic acid stability and use in cosmetic formulas.
null
null
cosmetics2030248_makarova
0
The article is well written, and the overall study was well planned and professionally conducted.
null
null
Round 1: and Author Response The article titled “Thermal behavior and free-radical-scavenging activity of phytic acid alone and incorporated in galenic emulsions” is focused on the characterization of phytic acid stability and use in cosmetic formulas.
null
null
cosmetics2030248_makarova
0
However, I think that the article can be substantially improved if the following points are addressed: (1)
null
null
Second Round of Evaluation Round 2: and Author Response
null
null
cosmetics2030248_makarova
0
The article is well written, and the overall study was well planned and professionally conducted.
null
null
Second Round of Evaluation Round 2: and Author Response
null
null
cosmetics2030248_makarova
0
Second Round of Evaluation Round 2: and Author Response
null
null
The article is well written, and the overall study was well planned and professionally conducted.
null
null
cosmetics2030248_makarova
0
The article is well written, and the overall study was well planned and professionally conducted.
null
null
Round 1: and Author Response The article titled “Thermal behavior and free-radical-scavenging activity of phytic acid alone and incorporated in galenic emulsions” is focused on the characterization of phytic acid stability and use in cosmetic formulas.
null
null
cosmetics2030248_makarova
0